Handelsbanken Fonder AB Has $15.85 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Handelsbanken Fonder AB boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 2.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 742,184 shares of the company’s stock after buying an additional 21,222 shares during the quarter. Handelsbanken Fonder AB’s holdings in Kenvue were worth $15,846,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of KVUE. Huntington National Bank raised its stake in shares of Kenvue by 26.5% in the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company’s stock valued at $96,000 after acquiring an additional 871 shares in the last quarter. ING Groep NV raised its position in shares of Kenvue by 23.6% in the third quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock valued at $82,727,000 after purchasing an additional 681,954 shares during the period. Golden State Equity Partners lifted its stake in shares of Kenvue by 716.1% in the fourth quarter. Golden State Equity Partners now owns 25,658 shares of the company’s stock worth $548,000 after buying an additional 22,514 shares during the last quarter. Empower Advisory Group LLC bought a new stake in shares of Kenvue during the 4th quarter worth $48,252,000. Finally, Everence Capital Management Inc. grew its stake in Kenvue by 122.1% in the 4th quarter. Everence Capital Management Inc. now owns 45,380 shares of the company’s stock valued at $969,000 after buying an additional 24,950 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 4.1 %

Shares of Kenvue stock opened at $23.31 on Friday. The company’s fifty day moving average price is $21.29 and its two-hundred day moving average price is $22.14. The firm has a market capitalization of $44.68 billion, a PE ratio of 43.97, a price-to-earnings-growth ratio of 2.61 and a beta of 1.45. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.52%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio is 154.72%.

Analysts Set New Price Targets

A number of research firms have weighed in on KVUE. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. UBS Group cut their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Barclays decreased their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. Canaccord Genuity Group dropped their price target on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $23.00.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.